Skip to main content
    E

    Evolus Inc (EOLS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $6.69
    +0.06 (+0.91%)

    Market Cap: $438.83M

    Last updated: Nov 17, 2026 at 4:26 PM ET

    Evolus Inc (EOLS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Evolus (EOLS) has a market cap of $438.83M and an enterprise value of $554.03M. It earned -$31.11M on revenue of $325.47M over the last 12 months.

    Total Valuation

    Enterprise value is 26.25% above the market cap, as debt exceeds cash.

    Market Cap$438.83M
    Enterprise Value$554.03M
    Latest price (Nov 17, 2026)$6.69

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.24% in the quarter ended Sep 30, 2026 and grew 2.30% a year over 2 years.

    Shares Outstanding66.09M
    Shares Change (YoY)+2.10%
    Shares Change (QoQ)+0.24%
    Share Count Growth (2Y CAGR)+2.30%

    Valuation Ratios

    The price to sales ratio is 1.4x. Its year-end P/S ranged from 1.4x to 10.2x from 2019 to 2025.

    P/S Ratio1.4x
    Forward P/S1.3x

    Price Statistics

    The stock is down 7.34% over 52 weeks and trades 11.04% below its 50-day average.

    Beta (1Y)1.34
    52-Week Change-7.34%
    1-Month Change-9.10%
    3-Month Change-22.21%
    6-Month Change+4.04%
    5-Year Change-6.01%
    Total Return (1Y)-7.34%
    Total Return (3Y CAGR)-10.65%
    Total Return (5Y CAGR)+0.27%
    Return vs SPY (1Y)-16.40%
    Max Drawdown (1Y)-45.43%
    Max Drawdown (3Y)-77.47%
    Sharpe Ratio (1Y)-0.08
    Correlation with SPY (1Y)0.29
    50-Day Average$7.52
    200-Day Average$6.39
    52-Week Range$3.86 to $9.31
    RSI (14 Days)41.0
    Average Volume (20 Days)1.09M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.42x current liabilities.

    Current Ratio1.42x
    Quick Ratio0.84x
    Interest Coverage-0.92x

    Returns and Efficiency

    Return on invested capital is -12.69% over the last 12 months, against a 5-year average of -26.99%.

    Return on Assets (ROA)-10.96%
    Return on Invested Capital (ROIC)-12.69%
    Return on Capital Employed (ROCE)-10.68%
    ROA (5Y Average)-27.43%
    ROIC (5Y Average)-26.99%
    Asset Turnover1.29x
    Inventory Turnover1.77x
    Receivables Turnover5.31x
    Cash Conversion Cycle57 days

    Scores

    EOLS has an Altman Z-Score of -1.37, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-1.37
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $325.47M over the last 12 months is up 13.87% from the 12 months before.

    Revenue$325.47M
    Revenue Growth (YoY)+13.87%
    Gross Profit$216.05M
    Operating Income-$15.60M
    Pretax Income-$30.34M
    Net Income-$31.11M
    EBITDA-$2.63M
    EBIT-$15.11M
    Reported EPS (TTM)-$0.29

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$41.70M
    Total Debt$156.90M
    Net Debt$115.20M
    Net Debt Per Share$1.74
    Working Capital$59.36M
    Shareholder Equity-$37.81M
    Tangible Book Value-$105.75M
    Total Assets$283.82M
    Total Liabilities$321.64M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $5.59M of capital spending, operating cash flow left -$8.23M of free cash flow.

    Operating Cash Flow-$2.65M
    Capital Expenditures$5.59M
    Free Cash Flow-$8.23M
    FCF Per Share-$0.12
    Depreciation and Amortization$12.48M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -4.79%, against a 5-year average of -27.36%.

    Gross Margin66.38%
    Operating Margin-4.79%
    Pretax Margin-9.32%
    Net Margin-9.56%
    EBITDA Margin-0.81%
    EBIT Margin-4.64%
    FCF Margin-2.53%
    Gross Margin (5Y Average)63.92%
    Operating Margin (5Y Average)-27.36%
    Net Margin (5Y Average)-32.77%

    Growth

    Revenue grew 25.98% a year over 3 years.

    Revenue Growth (3Y CAGR)+25.98%
    Revenue Growth (5Y CAGR)+39.36%

    Revenue and profit by year

    Dividends and Yields

    EOLS does not pay a dividend. Its free cash flow yield is -1.86%.

    FCF Yield-1.86%
    Buyback Yield-0.12%
    Shareholder Yield-0.12%

    Peer Position

    Against 10 similar companies, EOLS has the 7th highest P/S.

    P/S Ratio1.4x vs 1.8x median
    ROIC-12.69% vs -3.84% median
    Revenue Growth (Trailing 4 Quarters, YoY)+13.87% vs +15.45% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 14.65% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+14.65%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About EOLS

    What is EOLS's market cap?

    Evolus has a market cap of $438.83M. Its enterprise value, which adds debt and subtracts cash, is $554.03M.

    How many shares of EOLS are outstanding?

    Evolus has 66.09M shares outstanding. The count is up 2.10% from a year earlier.

    Does EOLS pay a dividend?

    No. Evolus does not pay a dividend.

    How much debt does EOLS have?

    Evolus has $156.90M of total debt and $41.70M of cash and equivalents, a net debt position of $115.20M.